Point72 Asset Management L.P. Acquires New Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Point72 Asset Management L.P. purchased a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 849,621 shares of the biotechnology company's stock, valued at approximately $7,630,000. Point72 Asset Management L.P. owned approximately 0.59% of Aurinia Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AUPH. ProShare Advisors LLC boosted its stake in Aurinia Pharmaceuticals by 31.9% in the fourth quarter. ProShare Advisors LLC now owns 44,588 shares of the biotechnology company's stock valued at $400,000 after acquiring an additional 10,771 shares in the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 10.2% in the 4th quarter. Nuveen Asset Management LLC now owns 1,492,301 shares of the biotechnology company's stock valued at $13,401,000 after purchasing an additional 138,054 shares during the last quarter. Millennium Management LLC boosted its position in shares of Aurinia Pharmaceuticals by 49.9% in the 4th quarter. Millennium Management LLC now owns 87,421 shares of the biotechnology company's stock valued at $785,000 after purchasing an additional 29,096 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Aurinia Pharmaceuticals by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,314 shares of the biotechnology company's stock worth $685,000 after buying an additional 2,887 shares during the last quarter. Finally, Lazard Asset Management LLC grew its stake in Aurinia Pharmaceuticals by 341.9% during the 4th quarter. Lazard Asset Management LLC now owns 596,389 shares of the biotechnology company's stock worth $5,355,000 after buying an additional 461,430 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.

Aurinia Pharmaceuticals Stock Performance

Aurinia Pharmaceuticals stock traded down $0.07 during midday trading on Thursday, hitting $8.27. 1,667,967 shares of the company's stock were exchanged, compared to its average volume of 1,325,563. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -55.13 and a beta of 1.16. Aurinia Pharmaceuticals Inc. has a 12-month low of $5.11 and a 12-month high of $10.67. The firm's 50 day simple moving average is $8.02 and its 200 day simple moving average is $8.26.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.08. The business had revenue of $62.47 million during the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. Equities research analysts predict that Aurinia Pharmaceuticals Inc. will post 0.11 EPS for the current year.

Insiders Place Their Bets

In other Aurinia Pharmaceuticals news, insider Greg Keenan sold 12,239 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $97,912.00. Following the transaction, the insider now directly owns 161,789 shares of the company's stock, valued at approximately $1,294,312. The trade was a 7.03% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Peter Greenleaf sold 195,593 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the transaction, the chief executive officer now owns 1,953,892 shares of the company's stock, valued at approximately $15,631,136. The trade was a 9.10% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 343,898 shares of company stock valued at $2,753,094. 4.30% of the stock is owned by company insiders.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.